10 completed, 2 terminated, 2 unknown, 1 no longer available. 5 Phase 2, 5 Phase 3, 3 Phase 4, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Unknown 1 |
| Phase 3 | 5 | Completed 5 |
| Phase 4 | 3 | Terminated 2, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
Follow bamlanivimab: new trials by email Literature Review of bamlanivimab trials Research Report on bamlanivimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2 Bamlanivimab, Bamlanivimab and Etesevimab Drug Combination, Casirivimab and Imdevimab Drug Combination - COVID-19 | Completed | University of Milano Bicocca | 251 | 2021-10-14 | 2025-03-30 | |
| A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19 Bamlanivimab, Standard of Care - Covid19 | Phase 4 | Unknown | Fraser Health | 576 | 2021-03-17 | 2021-08-26 |
| Treatment of Nosocomial COVID-19 Anti-SARS-CoV-2 mAb - Covid19, Nosocomial Infection | Phase 4 | Terminated | University of Calgary | 46 | 2021-02-12 | 2023-04-19 |
| A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) Bamlanivimab - COVID-19 | Phase 2 | Completed | Eli Lilly and Company | 109 | 2021-02-01 | 2021-11-16 |
| At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19 bamlanivimab - Covid19 | Phase 4 | Terminated | Daniel Griffin | 139 | 2021-01-04 | 2022-03-18 |
| Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB - Covid19 | Phase 2 | Unknown | Sohail Rao | 1000 | 2020-11-20 | 2022-03-29 |
| A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness Bamlanivimab, Etesevimab, Placebo - COVID-19 | Phase 2 | Completed | Eli Lilly and Company | 1755 | 2020-10-29 | 2022-07-01 |
| A Study of LY3819253 (LY-CoV555) in Healthy Participants LY3819253, Placebo - Healthy | Phase 1 | Completed | Eli Lilly and Company | 25 | 2020-09-02 | 2021-12-06 |
| ACTIV-2: A Study for Outpatients With COVID-19 bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19 | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 4044 | 2020-08-19 | 2024-08-02 |
| LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) LY3819253, Placebo, Remdesivir - COVID-19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 314 | 2020-08-05 | 2023-12-27 |
| ACTIV-3: Therapeutics for Inpatients With COVID-19 LY3819253, Placebo, Remdesivir - Covid19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 2753 | 2020-08-04 | 2023-08-25 |
| A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff Bamlanivimab, Placebo, Etesevimab - COVID-19, SARS-CoV2 | Phase 3 | Completed | Eli Lilly and Company | 1180 | 2020-08-02 | 2022-02-04 |
| A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness LY3819253, LY3832479, LY3853113 - COVID-19 | Phase 2 / Phase 3 | Completed | Eli Lilly and Company | 3307 | 2020-06-17 | 2024-04-11 |
| A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 LY3819253, Placebo - COVID-19 | Phase 1 | Completed | Eli Lilly and Company | 26 | 2020-05-28 | 2021-11-12 |
| Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19 Bamlanivimab - COVID-19 | No longer available | Eli Lilly and Company | 2023-10-02 |
COVID-19 (14) · Coronaviridae Infections (3) · Coronavirus Infections (3) · Nidovirales Infections (3) · RNA Virus Infections (3) · Severe Acute Respiratory Syndrome (3) · Virus Diseases (3) · Cross Infection (1)
Eli Lilly and Company (7) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Daniel Griffin (1) · Fraser Health (1) · Sohail Rao (1) · University of Calgary (1) · University of Milano Bicocca (1)
United States (11) · Canada (3) · Argentina (2) · Denmark (2) · Puerto Rico (2) · Singapore (2) · Spain (2) · Brazil (1) · Greece (1) · Guatemala (1) · Italy (1) · Mexico (1) · Nigeria (1) · Philippines (1) · Poland (1)
Alain Tremblay (1) · Dan Griffin, MD, PHD (1) · David Smith, MD, MAS (1) · James Neaton, Prof. (1) · Jens Lundgren, Prof. (1) · Paolo Bonfanti, MD (1) · Prof. James Neaton (1) · Prof. Jens Lundgren (1) · Robert Fowler (1) · Sohail Rao, MD (1) · Srinivas Murthy (1)
PMID 34473343, PMID 35713300, PMID 34374951, PMID 33356051, PMID 33113295, PMID 33475701, PMID 34081073, PMID 34260849, PMID 34346827, PMID 34718468, PMID 34928698, PMID 34953520, PMID 34981077, PMID 35298440, PMID 35493124, PMID 35793677, PMID 35797235, PMID 35817072, PMID 35939810, PMID 35995785, PMID 36210483, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36802755, PMID 37068272, PMID 37099295, PMID 37279602, PMID 37329415, PMID 37650230, PMID 37650232, PMID 37650233, PMID 37650236, PMID 37855026, PMID 37948759, PMID 38291279, PMID 39018444, PMID 39028902, PMID 39230829, PMID 39922466, PMID 40262279, PMID 42148571